$PRQR Announces Positive Results from Clinical Trial of QR-421a

٢٥ مارس ٢٠٢١

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)

QR-421a observed to be well tolerated with no serious adverse events reported

Two pivotal Phase 2/3 trials are expected to start by the end of 2021

finance.yahoo.com/news/proqr-announces-positive-results-clinical-110000726.html

٢٥ مارس ٢٠٢١

ملاحظة

Citigroup Reiterated buy $33 → $44